Cargando…
Validation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and Chlorthalidone
BACKGROUND: The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) is a randomized, double-blind, active-controlled trial designed to compare the rate of coronary heart disease events in high-risk hypertensive participants initially randomized to a diuretic (chlorth...
Autores principales: | Piller, Linda B, Davis, Barry R, Cutler, Jeffrey A, Cushman, William C, Wright, Jackson T, Williamson, Jeff D, Leenen, Frans HH, Einhorn, Paula T, Randall, Otelio S, Golden, John S, Haywood, L Julian |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC149403/ https://www.ncbi.nlm.nih.gov/pubmed/12459039 http://dx.doi.org/10.1186/1468-6708-3-10 |
Ejemplares similares
-
Comments on ALLHAT and doxazosin
por: Krakoff, Lawrence R
Publicado: (2001) -
Benefits and side effects of blood pressure lowering treatment: what was wrong with doxazosin in the ALLHAT?
por: Gavras, Irene, et al.
Publicado: (2001) -
Antihypertensive Drug Effects on Renal Function and Myocardial Infarction and Implications of the ALLHAT Study Results
por: Curtiss, Frederic R.
Publicado: (2003) -
Reappraisal of Antihypertensive Medicine Doxazosin and Carvedilol as a Potential Therapeutic for Hepatic Fibrosis
por: Paik, Yong-Han
Publicado: (2016) -
Impact of the ALLHAT Study Results on Managed Care
por: Anderson, Robert J.
Publicado: (2003)